Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma.

Next Previous
Trial Profile

Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Farletuzumab (Primary)
  • Indications Pituitary adenoma
  • Focus Therapeutic Use

Most Recent Events

  • 07 Feb 2011 Actual initiation date (Feb 2011) added as reported by ClinicalTrials.gov.
  • 07 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 23 Nov 2010 Planned initiation date changed from 1 Sep 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top